Skip to Content

Abacavir Dosage

Applies to the following strength(s): 300 mg ; 20 mg/mL

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

300 mg orally twice a day or 600 mg orally once a day

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection

Usual Adult Dose for Nonoccupational Exposure

US CDC recommendations: 300 mg orally twice a day or 600 mg orally once a day
Duration of therapy: 28 days

Comments:
-Recommended as part of alternative regimens (NNRTI-based, protease inhibitor-based, or triple NRTI) for nonoccupational postexposure prophylaxis of HIV infection
-Prophylaxis should be started as soon as possible, within 72 hours of exposure.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Occupational Exposure

US Public Health Service working group recommendations: 300 mg orally twice a day or 600 mg orally once a day
Duration of therapy: 28 days, if tolerated

Comments:
-Only with expert consultation, as part of an alternative regimen for use as HIV postexposure prophylaxis
-Prophylaxis should be started as soon as possible, preferably within hours after exposure.
-The optimal duration of prophylaxis is unknown and may differ based on institution protocol.
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for HIV Infection

3 months or older:
Oral solution: 8 mg/kg orally twice a day or 16 mg/kg orally once a day
Maximum dose: 600 mg/day

Tablets:
14 to less than 20 kg: 150 mg orally twice a day or 300 mg orally once a day
20 to less than 25 kg: 150 mg orally in the morning and 300 mg in the evening, or 450 mg orally once a day
25 kg or more: 300 mg orally twice a day or 600 mg orally once a day

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Mild liver dysfunction (Child-Pugh score 5 to 6): 200 mg orally twice a day
Moderate or severe liver dysfunction: Contraindicated

Precautions

US BOXED WARNINGS:
HYPERSENSITIVITY REACTIONS:
-Serious and sometimes fatal hypersensitivity reactions associated with this drug; this multi-organ clinical syndrome generally characterized by key signs/symptoms including fever, rash, constitutional (including generalized malaise, fatigue, achiness), gastrointestinal (including nausea, vomiting, diarrhea, abdominal pain), and respiratory (including pharyngitis, dyspnea, cough). This drug should be discontinued as soon as a hypersensitivity reaction is suspected.
-Patients with the human leukocyte antigen subtype B*5701 (HLA-B*5701) allele are at increased risk of hypersensitivity reaction to this drug; such reactions have occurred in HLA-B*5701-negative patients, but considerably less often than in HLA-B*5701-positive patients. To reduce risk of hypersensitivity, all patients should be screened for the HLA-B*5701 allele before starting this drug; screening also recommended before restarting therapy in patients with unknown HLA-B*5701 status who previously tolerated the drug.
-Regardless of HLA-B*5701 status, this drug should be permanently discontinued if hypersensitivity cannot be ruled out, even if other diagnoses possible.
-After a hypersensitivity reaction to abacavir, this drug (or any other abacavir-containing product) should never be restarted; more severe symptoms can occur within hours and may include life-threatening hypotension and death.
-Serious or fatal hypersensitivity reactions can occur with resumption of this drug (or any other abacavir-containing product), even in patients with no identified history or unrecognized symptoms of abacavir hypersensitivity; such reactions can occur within hours.

LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY:
-Lactic acidosis and severe hepatomegaly with steatosis (including fatalities) reported with nucleoside analogs alone or in combination with other antiretrovirals.

Safety and efficacy have not been established in patients younger than 3 months.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Use in combination with other antiretroviral agents.
-May administer without regard to food
-If patient is unable to reliably swallow a tablet, use the oral solution.
-Consult the manufacturer product information regarding missed doses.

Storage requirements:
-Oral solution: Store at 20C to 25C (68F to 77F); may refrigerate; do not freeze.
-Tablets: Store at 20C to 25C (68F to 77F).

General:
-Before starting this drug, medical history should be reviewed for prior exposure to any abacavir-containing product (to prevent reintroduction in patient with history of abacavir hypersensitivity).
-All patients with unknown HLA-B*5701 status should be screened for the HLA-B*5701 allele before starting or restarting this drug.

Monitoring:
-Hypersensitivity: For symptoms of hypersensitivity reaction in patients restarting the drug

Patient advice:
-Always read the Medication Guide and Warning Card (with information about abacavir hypersensitivity reaction) dispensed with each new and refill prescription; carry the Warning Card.
-If this drug is stopped for any reason, do not restart it (or any other abacavir-containing product) without consulting physician; medical care must be readily accessible.

Hide